Identification

Summary

Oxandrolone is an androgenic hormone used to treat muscle loss from prolonged corticosteroid treatment and to treat bone pain associated with osteoporosis.

Brand Names
Oxandrin
Generic Name
Oxandrolone
DrugBank Accession Number
DB00621
Background

A synthetic hormone with anabolic and androgenic properties.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 306.4397
Monoisotopic: 306.219494826
Chemical Formula
C19H30O3
Synonyms
  • Ossandrolone
  • Oxandrolon
  • Oxandrolona
  • Oxandrolone
  • Oxandrolonum
External IDs
  • CB 8075
  • NSC-67068
  • SC 11585
  • SC-11585

Pharmacology

Indication

Use to promote weight gain after weight loss following extensive surgery.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Oxandrolone is an anabolic steroids indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Anabolic steroids are synthetic derivatives of testosterone.

Mechanism of action

Oxandrolones interact with androgen receptors in target tissues.

TargetActionsOrganism
AAndrogen receptor
agonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Renal

Route of elimination

Not Available

Half-life

0.55 hours (1st phage), 9 hours (2nd phase)

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The oral LD50 of oxandrolone in mice and dogs is greater than 5,000 mg/kg.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseOxandrolone may increase the hypoglycemic activities of Acarbose.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Oxandrolone.
AcetohexamideThe metabolism of Acetohexamide can be decreased when combined with Oxandrolone.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Oxandrolone.
AlbiglutideOxandrolone may increase the hypoglycemic activities of Albiglutide.
AllantoinThe therapeutic efficacy of Allantoin can be increased when used in combination with Oxandrolone.
AlogliptinOxandrolone may increase the hypoglycemic activities of Alogliptin.
AlosetronThe metabolism of Alosetron can be decreased when combined with Oxandrolone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Oxandrolone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Oxandrolone.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
International/Other Brands
Anavar (Pfizer Inc.) / Xtendrol (Atlantis)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OxandrinTablet10 mg/1OralPhysicians Total Care, Inc.2005-09-132011-06-30US flag
OxandrinTablet2.5 mg/1OralSavient Pharmaceuticals2007-04-09Not applicableUS flag
OxandrinTablet2.5 mg/1OralPhysicians Total Care, Inc.2005-09-132011-06-30US flag
OxandrinTablet10 mg/1OralSavient Pharmaceuticals2007-04-09Not applicableUS flag
OxandroloneTablet10 mg/1OralActavis Pharma Company2007-01-012014-04-30US flag
OxandroloneTablet2.5 mg/1OralActavis Pharma Company2007-01-012015-04-30US flag00591 3544 01 nlmimage10 a71b53da
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OxandroloneTablet2.5 mg/1OralUpsher-Smith Laboratories, LLC2006-12-01Not applicableUS flag00245 0271 11 nlmimage10 283c9444
OxandroloneTablet2.5 mg/1OralPar Pharmaceutical, Inc.2007-08-20Not applicableUS flag
OxandroloneTablet10 mg/1OralA S Medication Solutions2007-08-20Not applicableUS flag
OxandroloneTablet2.5 mg/1Oralbryant ranch prepack2007-08-20Not applicableUS flag
OxandroloneTablet10 mg/1OralEon Labs, Inc.2006-12-012013-01-11US flag
OxandroloneTablet10 mg/1OralAmerican Health Packaging2015-12-092020-03-31US flag
OxandroloneTablet10 mg/1OralUpsher-Smith Laboratories, LLC2007-03-22Not applicableUS flag
OxandroloneTablet10 mg/1OralPar Pharmaceutical, Inc.2007-08-20Not applicableUS flag
OxandroloneTablet2.5 mg/1OralEon Labs, Inc.2006-12-012013-01-11US flag
OxandroloneTablet2.5 mg/1OralAmerican Health Packaging2012-11-142020-03-31US flag

Categories

ATC Codes
A14AA08 — Oxandrolone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as steroid lactones. These are sterol lipids containing a lactone moiety linked to the steroid skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Steroid lactones
Alternative Parents
17-hydroxysteroids / 3-oxo-5-alpha-steroids / Oxasteroids and derivatives / Naphthopyrans / Naphthalenes / Delta valerolactones / Pyrans / Oxanes / Tertiary alcohols / Cyclic alcohols and derivatives
show 6 more
Substituents
17-hydroxysteroid / 2-oxasteroid / 3-oxo-5-alpha-steroid / 3-oxosteroid / Alcohol / Aliphatic heteropolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic alcohol
show 18 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
3-oxo steroid, 17beta-hydroxy steroid, anabolic androgenic steroid, oxa-steroid (CHEBI:7820) / Androstane and derivatives (C07346)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
7H6TM3CT4L
CAS number
53-39-4
InChI Key
QSLJIVKCVHQPLV-PEMPUTJUSA-N
InChI
InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
IUPAC Name
(1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyl-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C

References

Synthesis Reference

John Cabaj, "Process for the synthesis of oxandrolone." U.S. Patent US20030032817, issued February 13, 2003.

US20030032817
General References
  1. Demling RH, DeSanti L: Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns. 2003 Dec;29(8):793-7. [Article]
Human Metabolome Database
HMDB0014759
KEGG Drug
D00462
KEGG Compound
C07346
PubChem Compound
5878
PubChem Substance
46509027
ChemSpider
5667
RxNav
7779
ChEBI
7820
ChEMBL
CHEMBL1200436
ZINC
ZINC000003813047
Therapeutic Targets Database
DAP000905
PharmGKB
PA164749395
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxandrolone
FDA label
Download (40.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHIV Wasting Syndrome1
3CompletedSupportive CareUnspecified Adult Solid Tumor, Protocol Specific / Weight Changes1
3TerminatedTreatmentPressure Ulcers1
2CompletedTreatmentDwarfism / Turners Syndrome1
2CompletedTreatmentKlinefelter's Syndrome1
2CompletedTreatmentTurners Syndrome1
2RecruitingTreatmentRotator Cuff Tears1
2WithdrawnTreatmentAnemia / Functional Iron Deficiency / Traumas1
2, 3CompletedTreatmentBurns1
2, 3TerminatedTreatmentBurns1

Pharmacoeconomics

Manufacturers
  • Savient pharmaceuticals inc
  • Par pharmaceutical inc
  • Roxane laboratories inc
  • Sandoz inc
  • Upsher smith laboratories inc
Packagers
  • A-S Medication Solutions LLC
  • BTG Pharmaceuticals Corp.
  • DSM Corp.
  • Eon Labs
  • Letco Medical Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Par Pharmaceuticals
  • Pharmaceutics International Inc.
  • Physicians Total Care Inc.
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Savient Pharmaceuticals
  • Upsher Smith Laboratories
  • Watson Pharmaceuticals
Dosage Forms
FormRouteStrength
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Oxandrin 10 mg tablet27.02USD tablet
Oxandrolone 10 mg tablet18.31USD tablet
Oxandrolone 100% powder9.54USD g
Oxandrin 2.5 mg tablet8.08USD tablet
Oxandrolone 2.5 mg tablet5.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6670351No2003-12-302012-10-20US flag
US5872147No1999-02-162017-12-05US flag
US6090799No2000-07-182017-07-18US flag
US6576659No2003-06-102017-12-05US flag
US6828313No2004-12-072017-12-05US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)236.5 °CPhysProp
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.014 mg/mLALOGPS
logP3.36ALOGPS
logP2.95ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)-0.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity84.75 m3·mol-1ChemAxon
Polarizability35.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.9537
Caco-2 permeable+0.6616
P-glycoprotein substrateSubstrate0.6489
P-glycoprotein inhibitor INon-inhibitor0.5085
P-glycoprotein inhibitor IINon-inhibitor0.7936
Renal organic cation transporterNon-inhibitor0.7934
CYP450 2C9 substrateNon-substrate0.7807
CYP450 2D6 substrateNon-substrate0.8763
CYP450 3A4 substrateSubstrate0.7065
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.7894
CYP450 2D6 inhibitorNon-inhibitor0.966
CYP450 2C19 inhibitorNon-inhibitor0.8868
CYP450 3A4 inhibitorNon-inhibitor0.8455
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9822
Ames testNon AMES toxic0.9499
CarcinogenicityNon-carcinogens0.9501
BiodegradationNot ready biodegradable0.9469
Rat acute toxicity1.5177 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9712
hERG inhibition (predictor II)Non-inhibitor0.7133
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Juul A: The effects of oestrogens on linear bone growth. Hum Reprod Update. 2001 May-Jun;7(3):303-13. [Article]
  2. Zhao J, Bauman WA, Huang R, Caplan AJ, Cardozo C: Oxandrolone blocks glucocorticoid signaling in an androgen receptor-dependent manner. Steroids. 2004 May;69(5):357-66. [Article]
  3. Bi LX, Wiren KM, Zhang XW, Oliveira GV, Klein GL, Mainous EG, Herndon DN: The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4. [Article]
  4. Cadwallader AB, Rollins DE, Lim CS: Effect of anabolic-androgenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocation. Mol Pharm. 2010 Jun 7;7(3):689-98. doi: 10.1021/mp900259w. [Article]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB: Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17. [Article]

Drug created at June 13, 2005 13:24 / Updated at May 06, 2021 01:26